
    
      Pembrolizumab has been approved by the U.S. Food and Drug Administration for the treatment of
      patients with Glioblastoma and Melanoma The Expanded Access Program (EAP) for this medicine
      in the U.S. is closed. The EAP will continue outside the U.S.
    
  